Hoth Therapeutics (HOTH), Tuesday reported that its experimental topical gel, HT-001, achieved primary efficacy in at least one key dermatologic metric for 100 percent of patients in its Phase 2a CLEER-001 study addressing skin side effects from EGFR inhibitors.
EGFR inhibitors, used in cancers such as non-small cell lung and colorectal, often provoke painful rashes, itching, dryness, nail issues, and hair loss, leading many patients to reduce or halt therapy.
In CLEER-001, over 65% of participants experienced meaningful relief from pain and pruritus, and none required dose adjustments or treatment discontinuation. HT-001, applied once daily, leverages an FDA-approved neurokinin-1 receptor antagonist to dampen Substance P-driven inflammation without systemic immunosuppression.
Supported by preclinical data showing reduced dermatitis and alopecia in erlotinib-treated rats, HT-001 is advancing with Phase 2b/3 trials now in planning.
HOTH is currently trading at $1.25, up $0.03 or 2.45 percent on hte Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.